|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Depreciation and amortization | |||||
| Amortization of discount on investment securities | |||||
| Share-based compensation expense | |||||
| Deferred tax expense / (income) | |||||
| Royalty financing agreement interest expense, net of interest paid | |||||
| Deferred tax expense | |||||
| Changes in fair value of contingent consideration and derivative financial instrument, net | |||||
| Changes in fair value of contingent consideration | |||||
| Changes in fair value of liability related to pre-funded warrants | |||||
| Unrealized foreign exchange (gains) / losses, net | |||||
| Other items, net | |||||
| Changes in operating assets and liabilities: | |||||
| Accounts receivable, prepaid expenses, and other current assets and receivables | |||||
| Accounts payable | |||||
| Accrued expenses, other liabilities, and operating leases | |||||
| Contingent consideration milestone payments | |||||
| Inventories | |||||
| Contract asset related to CSL Behring milestone payments | |||||
| Net cash used in operating activities | |||||
| Cash flows from investing activities | |||||
| Proceeds on maturity of debt securities | |||||
| Investment in debt securities | |||||
| Divestment of commercial manufacturing facility | |||||
| Purchases of property, plant, and equipment | |||||
| Net cash (used in) / generated from investing activities | |||||
| Cash flows from financing activities | |||||
| Proceeds from royalty financing agreement | |||||
| Payment of debt issuance costs | |||||
| Proceeds from follow-on public offerings of ordinary shares, net of issuance costs | |||||
| Proceeds from issuance of pre-funded warrants, net of issuance costs | |||||
| Proceeds from issuance of ordinary shares related to employee stock options and purchase plans | |||||
| Repayment of long-term debt | |||||
| Contingent consideration milestone payments | |||||
| Proceeds from royalty financing agreement, net of issuance costs | |||||
| Net cash generated from / (used in) financing activities | |||||
| Currency effect on cash, cash equivalents and restricted cash | |||||
| Net (decrease) / increase in cash, cash equivalents and restricted cash | |||||
| Cash, cash equivalents and restricted cash at the beginning of period | |||||
| Cash, cash equivalents and restricted cash at the end of period | |||||
| Supplemental cash flow disclosures: | |||||
| Cash paid for interest | |||||
| Non-cash decrease in accounts payables and accrued expenses and other current liabilities related to purchases of property, plant, and equipment | |||||
| Cash and cash equivalents | |||||
| Restricted cash related to leasehold and other deposits | |||||
Loading...
